Securities and Exchange Commission
Washington, D.C. 20549
Information to be Included in Statements Filed Pursuant
to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed
Pursuant to § 240.13d-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)*
Treace Medical Concepts, Inc.
(Name of Issuer)
Common Stock, $0.001 par value
(Title of Class of Securities)
December 31, 2022
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☐ Rule 13d-1(c)
☒ Rule 13d-1(d)
The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|CUSIP No. 89455T109||Schedule 13G||Page 1 of 5|
Names of Reporting Persons
John R. Treace
Check the Appropriate Box if a Member of a Group
(a) ☐ (b) ☐
SEC Use Only
Citizenship or Place of Organization
Sole Voting Power
Shared Voting Power
Sole Dispositive Power
Shared Dispositive Power
Aggregate Amount Beneficially Owned by Each Reporting Person
Check if the Aggregate Amount in Row (9) Excludes Certain Shares
Percent of Class Represented by Amount in Row 9
Type of Reporting Person
|CUSIP No. 89455T109||Schedule 13G||Page 2 of 5|
|ITEM 1.|| |
(a) Name of Issuer:
Treace Medical Concepts, Inc. (the Issuer).
Address of Issuers Principal Executive Offices:
100 Palmetto Park Place, Ponte Vedra, Florida 32081
|ITEM 2.|| |
(a) Name of Person Filing:
This statement is filed on behalf of John R. Treace (the Reporting Person).
Address or Principal Business Office:
The business address of the Reporting Person is c/o Treace Medical Concepts, Inc., 100 Palmetto Park Place, Ponte Vedra, Florida 32081.
Citizenship of each Reporting Person is:
The Reporting Person is a citizen of the United States.
Title of Class of Securities:
Common stock, $0.001 par value (Common Stock).
|ITEM 3.|| |
|CUSIP No. 89455T109||Schedule 13G||Page 3 of 5|
|ITEM 4.|| |
The ownership information presented below represents beneficial ownership of Common Stock of the Issuer as of December 31, 2022, based upon 55,501,742 shares of Common Stock outstanding as of November 3, 2022, as disclosed in the Issuers Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2022.
vote or to
Sole power to
John R. Treace
John R. Treace may be deemed the beneficial owner of 2,385,033 shares of Common Stock, which includes (i) 872,780 shares of Common Stock held of record by the Reporting Person and his spouse as joint tenants, (ii) 408,816 shares of Common Stock held of record by a family trust for which the Reporting Persons spouse is a co-trustee, (iii) 535,000 shares of Common Stock held of record by a family trust, of which the Reporting Person is co-trustee, and (iv) 568,437 shares of Common Stock held of record by a family trust, of which the Reporting Person is co-trustee.
|ITEM 5.|| |
Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☒
|ITEM 6.|| |
Ownership of More than Five Percent on Behalf of Another Person.
|ITEM 7.|| |
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
|ITEM 8.|| |
Identification and Classification of Members of the Group.
|CUSIP No. 89455T109||Schedule 13G||Page 4 of 5|
|ITEM 9.|| |
Notice of Dissolution of Group.
|ITEM 10.|| |
|CUSIP No. 89455T109||Schedule 13G||Page 5 of 5|
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: February 13, 2023
|John R. Treace|